期刊
JOURNAL OF PROTEOME RESEARCH
卷 9, 期 11, 页码 5960-5968出版社
AMER CHEMICAL SOC
DOI: 10.1021/pr100747p
关键词
sialyl Lewis x antigen; CHO-131 antibody; immunoaffinity chromatography; targeted proteomics; sialylation; glycosylation; GlcNAc-beta-(1,6)- branching; breast cancer; posttranslational modification; quantification; plasma
资金
- US National Institutes of Health [U24-CA-126480]
- National Cancer Institute Clinical Proteomic Technology Assessment for Cancer (CPTAC) consortium involving the Broad Institute of MIT and Harvard
- Memorial Sloan-Kettering Cancer Center
- Purdue University
- University of California, San Francisco
- Vanderbilt University School of Medicine
- Purdue Cancer Center
- Bindley Bioscience Center
Recent studies have shown that antibodies targeting Lewis x (Le(x)) antigen are a valuable tool in the isolation and identification of glycoproteins in plasma. A focus of this study was to determine whether sialylated Lewis x (sLe(x)) antigen carrying glycoproteins occur in human plasma and whether an antibody targeting this antigen could be used to isolate and identify glycoproteins bearing this antigen. An additional objective was to determine the degree to which proteins conjugated to Le(x) and sLe(x) antigens are similar in structure. A specific anti-sLe(x) antibody (anti-sLe(x)Ab), CHO-131, immobilized in an immunoaffinity column was used to select a set of specific sLe(x) bearing proteins from human plasma, after which they were identified by either of two analytical strategies. One approach was to further resolve the affinity selected proteins by reversed phase chromatography (RPC), tryptic digest the RPC fractions, and identify peptide fragments by MALDI-MS/MS. The second was to tryptic digest the affinity selected protein fraction, further resolve the tryptic fragments by RPC, and identify peptides from RPC fractions by MALDI-MS/MS. Histidine-rich glycoprotein, plasminogen, apolipoprotein A-I, vitronectin, proteoglycan-4, clusterin, Ig gamma-2 chain C region, Ig mu chain C region, and interalpha-trypsin inhibitor heavy chain H4 were found to change three folds or more in association with breast cancer. Fifty percent of the glycoproteins carrying either sLe(x) antigen from CHO-131 selection, Le(x) antigen from selection with TG-1 antibody, or both were found to be changed three folds or more in concentration in breast cancer plasma relative to controls.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据